Equities Analysts Issue Forecasts for CLDX Q1 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for Celldex Therapeutics in a note issued to investors on Friday, February 28th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings per share of ($0.73) for the quarter. HC Wainwright has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The firm had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million.

A number of other research analysts also recently issued reports on CLDX. UBS Group began coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $44.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Finally, The Goldman Sachs Group reduced their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a research report on Monday. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $55.38.

Celldex Therapeutics Stock Performance

CLDX opened at $20.00 on Monday. Celldex Therapeutics has a one year low of $18.61 and a one year high of $50.76. The stock has a market capitalization of $1.33 billion, a P/E ratio of -7.78 and a beta of 1.60. The business’s 50-day simple moving average is $23.64 and its 200-day simple moving average is $28.70.

Hedge Funds Weigh In On Celldex Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP lifted its stake in shares of Celldex Therapeutics by 14.5% in the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock worth $314,190,000 after acquiring an additional 1,167,659 shares during the period. Vanguard Group Inc. lifted its position in Celldex Therapeutics by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company’s stock valued at $98,098,000 after purchasing an additional 12,213 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Celldex Therapeutics by 23.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company’s stock valued at $89,890,000 after purchasing an additional 676,771 shares during the period. Bellevue Group AG boosted its holdings in Celldex Therapeutics by 3.4% in the 3rd quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock valued at $104,404,000 after purchasing an additional 100,000 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its position in Celldex Therapeutics by 50.8% during the 4th quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company’s stock worth $63,579,000 after purchasing an additional 847,264 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.